Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985431 | 1.00 | CA12 (0.32) | CA12CA1CA2CA7CA14 | |
| SCHEMBL27729473 | 0.97 | CA12 (0.31) | CA12CA1CA2CA7CA14 | |
| SCHEMBL99578 | 0.89 | ALDH1A1 (0.42) | CA2TSHR | |
| SCHEMBL100142 | 0.88 | — | — | |
| SCHEMBL4273315 | 0.88 | CA12 (0.30) | CA12CA1CA2CA7CA14 | |
| SCHEMBL82931 | 0.88 | — | — | |
| SCHEMBL9955756 | 0.87 | — | — | |
| SCHEMBL198906 | 0.87 | LMNA (0.46) | TSHR | |
| SCHEMBL202435 | 0.84 | LMNA (0.50) | TSHR | |
| SCHEMBL200292 | 0.84 | LMNA (0.50) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1076 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558953-B1 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2021-05-19 | — | — | EP | claimed |
| US-10717747-B2 | Method for the manufacturing of 2-(3-(alkyl and alkenyl)morpholino)-ethan-1-ols | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2020-07-21 | — | — | US | claimed |
| EP-3558953-A1 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115111-A1 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2018-06-28 | — | — | WO | claimed |
| CN-102612514-B | Anti influenza agent | GRIFFITH UNIVERSITY (AU) | 2016-01-13 | — | — | CN | claimed |
| EP-2601166-A1 | COSMETIC PREPARATIONS | Cognis IP Management GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| US-20130131188-A1 | Cosmetic Preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2013-05-23 | — | — | US | claimed |
| EP-2426101-A1 | Cosmetic preparations | Cognis IP Management GmbH (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2012016642-A1 | COSMETIC PREPARATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2012-02-09 | — | — | WO | claimed |
| US-20090256111-A1 | DIALKYLBORANE AMINE COMPLEXES | BASF SE PATENTS, TRADEMARKS AND LICENSES (DE) | 2009-10-15 | — | — | US | claimed |
| EP-0984997-A1 | SILICON-BASED POLYCARBONATES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 2000-03-15 | — | — | EP | claimed |
| WO-1999003863-A1 | SILICON-CONTAINING CHAIN EXTENDERS | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1999-01-28 | — | — | WO | claimed |
| WO-1998054242-A1 | SILICON-BASED POLYCARBONATES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1998-12-03 | — | — | WO | claimed |
| EP-0426826-B1 | SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES | PHARMACIA AB (SE) | 1994-04-27 | — | — | EP | claimed |
| US-5212305-A | Cyclization and forming a carbon-nitrogen bond | KABI PHARMACIA AKTIBOLAG (SE) | 1993-05-18 | — | — | US | claimed |
| EP-0426826-A1 | SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES. | PHARMACIA AB (SE) | 1991-05-15 | — | — | EP | claimed |
| CN-1048218-A | The different azoles alkane and the different oxazoline compound that replace | PHARMACIA AB (SE) | 1991-01-02 | — | — | CN | claimed |
| WO-1990014342-A1 | SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES | PHARMACIA AB (SE) | 1990-11-29 | — | — | WO | claimed |
| US-4636382-A | ANTIPLAQUE | AB FERROSAN (SE) | 1987-01-13 | — | — | US | claimed |
| EP-0038785-B1 | NOVEL MORPHOLINO COUMPOUNDS | AB Ferrosan (SE) | 1985-11-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090256111-A1 | DIALKYLBORANE AMINE COMPLEXES | AOC1, DDC, AOC2 | CA12 2530/4885CA1 3842/4885CA2 3527/4885 |
| US-20130131188-A1 | Cosmetic Preparations | CYP1B1, CBR1, ACOX3 | CA12 3057/4885CA1 4471/4885CA2 2975/4885 |
| US-10717747-B2 | Method for the manufacturing of 2-(3-(alkyl and alkenyl)morpholino)-ethan-1-ols | THOP1, MDN1, CYP8B1 | CA12 4565/4885CA1 4875/4885CA2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.